SUBSCRIBE
SUBSCRIBE
News   Drug Development

Xanthus Pharmaceuticals, Inc. Initiates a Phase 1 Study of Clomet for Treatment of Solid Tumors

March 22, 2007 | 
1 min read
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals today announced the commencement of a Phase 1 dose escalation study of Clomet™ (DMPEN, 4-demethylpenclomedine) for the treatment of patients with solid tumors.
Clinical research Phase I
MORE ON THIS TOPIC
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
 · 
6 min read
 · 
Lori Ellis
3d rendering medical heart in yellow background
Cardiovascular disease
AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase III Trial
July 14, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Pictured: Takeda sign at its office in Massachusetts
Neuroscience
Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Depression
After Three Strikes, Relmada Abandons Depression Drug Esmethadone 
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac